Skip to content

Clinical Study for Liangxue Tongyu Prescription on Anti-inflammatory Effect of Intestinal Microflora and Its Metabolite SCFAs in Intracerebral Hemorrhage

Study for the Mechanism of Liangxue Tongyu Prescription on Anti-inflammatory Effect of Intestinal Microflora and Its Metabolite SCFAs in Intracerebral Hemorrhage Based on Brain-intestinal Interaction

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR1900002596
Enrollment
Unknown
Registered
2019-09-14
Start date
2019-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracerebral Hemorrhage

Interventions

Sponsors

Nanjing Hospital of Chinese Medcine Affiliated to Nanjing University of Chinese Medicine/Nanjing Hospital of Traditional Chinese Medcine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Consistent with the diagnostic criteria of intracerebral hemorrhage. 2. Syndrome differentiation of TCM belongs to the excess syndrome. 3. Hospitalized patients within 72 hours of onset. 4. 6 <= NIHSS <= 21. 5. Aged 18-85 years. 6. Patients who did not use hormones or gastrointestinal motility drugs before the first blood collection. 7. Sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with transient ischemic attack and cerebral infarction. 2. Subarachnoid hemorrhage and intracerebral hemorrhage caused by hematological diseases, tumors or trauma. 3. Severe aphasia and cognitive impairment occurred after the onset of the disease. 4. Patients with severe organic diseases of digestive system. 5. Allergic constitution. 6. Patients with severe primary diseases such as liver, kidney, hematopoietic system and endocrine system. 7. Pregnant or lactating women or patients who have recently had birth planning. 8. Persons with disabilities prescribed by law (blindness, deafness, dumbness, mental retardation, mental retardation and limb disability caused by other reasons affecting neurological impairment assessors). 9. Suspect or have a history of alcohol or drug abuse, or other situations that, according to the judgement of the researchers, may reduce the likelihood of enrollment or complicate the enrollment. 10. Patients who are participating in other clinical trials or Patients have participated in other drug clinical trials for less than three months.

Design outcomes

Primary

MeasureTime frame
NIHSS score;Activity of Daily Life Score;Gastrointestinal dysfunction score;Location and volume of cerebral hemorrhage and grading of cerebral edema; Clinical Symptom Score of Intestinal Function;Diagnostic scoring of apoplexy;

Countries

China

Contacts

Public ContactLi Jianxiang

Nanjing Hospital of Chinese Medcine Affiliated to Nanjing University of Chinese Medicine/Nanjing Hospital of Traditional Chinese Medcine

ljx029504@163.com+86 13002585870

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026